The Korean Journal of Medicine

  • 제80권1호
  • /
  • Pages.15-19
  • /
  • 2011
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지

만성 무증상 저나트륨혈증의 관리

Management of Chronic Asymptomatic Hyponatremia

  • 배은희 (전남대학교 의과대학 내과학교실)
  • Bae, Eun-Hui (Department of Internal Medicine, Chonnam National University Medical School)
  • 발행 : 2011.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

Hyponatremia is a common clinical problem in hospitalized patients and nursing home residents. It may also occur in healthy athletes after endurance exercise. The majority of patients with hyponatremia are asymptomatic and do not require immediate correction of the hyponatremia. While mild hyponatremia has traditionally been considered benign, symptomatic hyponatremia is a medical emergency requiring rapid correction to prevent the worsening of brain edema. However, it has been suggested that mild hyponatremia may be associated with gait disturbance, attention deficits, and an increased risk of falls, which may result in fracture, and its presence predicts a poor prognosis. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is among the most frequent causes of chronic hyponatremia. Hyponatremia must be corrected slowly (<10~12 mmol/L within the first 24 h, and <18 mmol/L within the first 48 h) to avoid osmotic myelinolysis. Fluid restriction and demeclocycline are the treatments for chronic hyponatremia used most widely. However, fluid restriction is of limited use because of poor long?term compliance and demeclocycline lacks broad availability. In controlled clinical trials vaptans (a vasopressin receptor antagonist) was efficacious in mild to moderate SIADH with an acceptable safety profile. However, its long?term use is currently impractical and more data are needed.

키워드

참고문헌

  1. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:71.e1-8. https://doi.org/10.1016/j.amjmed.2006.05.001
  2. Renneboog B, Decaux G. Determination of threshold for attention and gait deficits encountered in chronic hyponatremia [Abstract]. J Am Soc Nephrol 2006;17:37A.
  3. Schrier RW. Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol 2010;6:185.
  4. Lien YH, Shapiro JI. Hyponatremia: clinical diagnosis and management. Am J Med 2007;120:653-658. https://doi.org/10.1016/j.amjmed.2006.09.031
  5. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-S21.
  6. Decaux G, Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci 2003;326:25-30. https://doi.org/10.1097/00000441-200307000-00004
  7. Ellison DH, Berl T. Clinical practice: the syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-2072. https://doi.org/10.1056/NEJMcp066837
  8. Cox M, Guzzo J, Morrison G, Singer I. Demeclocycline and therapy of hyponatremia. Ann Intern Med 1977;86:113-114. https://doi.org/10.7326/0003-4819-86-1-113
  9. Curtis NJ, van Heyningen C, Turner JJ. Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremia. Age Ageing 2002;31:151-152. https://doi.org/10.1093/ageing/31.2.151
  10. White MG, Fetner CD. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. N Engl J Med 1975;292:390-392. https://doi.org/10.1056/NEJM197502202920803
  11. Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J 1981;283:1081-1083. https://doi.org/10.1136/bmj.283.6299.1081
  12. Schrier RW, Gross P, Gheorghiade M. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112. https://doi.org/10.1056/NEJMoa065181
  13. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-712. https://doi.org/10.1681/ASN.2009080857
  14. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007;27:447-457. https://doi.org/10.1159/000106456
  15. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297:1319-1331. https://doi.org/10.1001/jama.297.12.1319
  16. Greenberg A, Lehrich RW. Treatment of chronic hyponatremia: now we know how, but do we know when or if? J Am Soc Nephrol 2010;21:552-555. https://doi.org/10.1681/ASN.2010020157
  17. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624-1632. https://doi.org/10.1016/S0140-6736(08)60695-9